Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(11 sites)

Spain

Instituto Catalán de Oncología - Hospital Duran i Reynals, Barcelona, Barcelona

Hospital Universitario Marqués de Valdecilla (Santander), Santander, Cantabria

Centro Oncológico de Galicia (La Coruña), A Coruña, La Coruña

Hospital Clínico San Carlos, Madrid, Madrid

Hospital Universitario 12 de Octubre (Madrid), Madrid, Madrid